Tag: CAR-T therapy

Curocell’s CAR-T therapy Lymcato has passed the Health Insurance Review and Assessment Service’s drug reimbursement review, accelerating its path toward national health insurance coverage this year.

Abclon's CAR-T therapy project with Strike Pharma has been selected for the Eurostars international tech development program.

South Korea's first CAR-T therapy, Rimkato, moves closer to national health insurance reimbursement, with commercialization expected by year-end.

CureCell's CAR-T therapy Rimkato is the first approved in South Korea, enhancing access to treatment for blood cancer patients.

Curocell aims to lead in CAR-T therapies with RIMQARTO's approval, focusing on solid tumors and global expansion strategies.

HLB Innovation's SynKIR-310 shows improved antitumor activity and safety in preclinical trials, achieving 100% survival in mice.

Verismo Therapeutics' SynKIR-310 shows superior anti-tumor effects in preclinical studies, promising a safer CAR-T therapy for blood cancers.

HLB Group will present key findings on anti-cancer therapies at AACR 2026, highlighting SynKIR-110 and Lirafugratinib's advancements.